Morchella polysaccharide ameliorates myocardial infarction inflammation in mice through increasing gut
Hui-Min Su1, Jia-Xin Li1, Jun-Fang Wu2
1Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
Abstract:
Myocardial infarction (MI) initiates robust inflammatory responses. While moderate inflammation facilitates the clearance of necrotic debris, sustained inflammation promotes fibrosis and exacerbates MI progression. Fungal polysaccharides have shown significant anti-inflammatory activity, but role of Morchella polysaccharide (MCP) in modulating MI-associated inflammation remains unclear. In this study we investigated whether MCP ameliorated myocardial infarction injury and elucidated the underlying mechanisms focusing on the gut microbiota and associated metabolites. MI mice were established in mice by permanent ligation of the left anterior descending (LAD) coronary artery. MCP (200, 600 mg·kg-1·d-1. i.g.) was administered daily from D7 prior-MI induction and continued for 3 or 7 days post-MI. We showed that MCP administration significantly alleviated cardiac inflammation in post-MI mice. Metabolite screening identified 12-hydroxy-eicosapentaenoic acid (12-HEPE) as a critical mediator of MCP's anti-inflammatory effects. Intestinal metabolomic screening revealed that MCP markedly upregulated the abundance of the beneficial genus Lactobacillus. Eliminating the intestinal flora using a broad-spectrum antibiotic cocktail for 2 weeks abolished MCP-induced 12-HEPE elevation and anti-inflammation in post-MI mice. On the other hand, direct supplementation of 12-HEPE (200 µg·kg-1·d-1, i.p.) beginning 7 days prior to MI induction attenuated the inflammation. In conclusion, this study reveals that MCP attenuates post-MI inflammation by enriching beneficial gut bacteria such as Lactobacillus and increasing their metabolite 12-HEPE. MCP improves post-myocardial infarction (post-MI) inflammation and fibrotic repair by modulating gut microbiota and the intestinal lipid metabolite 12-HEPE. MCP treatment increases the abundance of the beneficial gut bacterium Lactobacillus. Concurrently, MCP enhances the activity of metabolic enzymes responsible for 12-HEPE synthesis within the improved intestinal microenvironment. This elevates intestinal 12-HEPE production and enhances its systemic circulation. Ultimately, increased serum 12-HPE levels attenuate cardiac inflammation and improve injury repair.
